School of Medicine
Showing 1-10 of 12 Results
Clinical Assistant Professor, Medicine - Hematology
Bio Dr. Iberri is a medical oncologist and hematologist who specializes in the treatment of hematologic malignancies. His clinical practices runs the gamut of malignant and non-malignant hematologic disorders including acute and chronic leukemias, multiple myeloma and lymphomas, and bleeding and thrombotic disorders. He is actively involved in clinical trials evaluating novel agents in hematologic malignancies. His research interests are in the development and application of biomarkers to select patients most likely to benefit from therapy.
Postdoctoral Research Fellow, Cardiovascular Medicine
Bio My long-term goal is to become a physician scientist and develop innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on my experience as a cardiologist for the past 5 years, I have become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin–angiotensin–aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, I moved to academia to conduct translational research. During my graduate training in the Egashira Lab, I focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. I obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. I realized the importance of translational research and the great potential of DDS to overcome many clinical problems. I developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. I published a first author paper and received academic awards for my novel science. Since becoming a postdoctoral fellow in the Yang Lab, I have continued to build upon my previous training in translational research. I am currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for the failing heart.
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
Bio Program Director (U.S) Japan Biodesign, Stanford Biodesign
Cardiovascular Medicine, Stanford University
Dr. Ikeno is a Research Associate, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406
Erik David Ingelsson
Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Health Research and Policy (Epidemiology)
Current Research and Scholarly Interests We are interested in the link between metabolic disturbances, such as obesity and insulin resistance, and the development of cardiovascular disease. Our research is translational and interdisciplinary, combining population-based studies with molecular biology to reach new insights into the pathophysiology of cardiovascular disease and related conditions, identification of new biomarkers for improved risk prediction, and discovery of novel drug targets.
John P.A. Ioannidis
C. F. Rehnborg Professor in Disease Prevention in the School of Medicine, Professor of Medicine, of Health Research and Policy (Epidemiology) and by courtesy, of Statistics and of Biomedical Data Science
Current Research and Scholarly Interests Meta-research
Clinical and molecular epidemiology
Human genome epidemiology
Reporting of research
Empirical evaluation of bias in research
Statistical methods and modeling
Meta-analysis and large-scale evidence
Prognosis, predictive, personalized, precision medicine and health
Sociology of science
Clinical Associate Professor, Medicine - Primary Care and Population Health
Bio Dr. Ip is Director of Clinical Therapeutics Curriculum for the Stanford University MSPA Program and Clinical Associate Professor in the Department of Medicine, Division of Primary Care and Population Health. He completed his Doctor of Pharmacy degree from UCSF School of Pharmacy and his post-graduate residency at Kaiser Permanente Santa Clara Medical Center. He is a clinical pharmacist specializing in diabetes and cardiovascular care. He established and currently co-leads the Diabetes Management Program at Kaiser Permanente Mountain View Medical Offices. He is also Chair and Professor of Clinical Sciences at Touro University California College of Pharmacy. Dr. Ip's research interests include anabolic steroids and performancing enhancing drugs as well as educational research.